Market Announcement

12 February 2020

Noxopharm Limited (ASX: NOX) – Trading Halt

Description

The securities of Noxopharm Limited ('NOX') will be placed in trading halt at the request of NOX, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Friday, 14 February 2020 or when the announcement is released to the market.

Issued by

Cheng Tang
Senior Adviser, Listings Compliance (Melbourne)

Date: 12 February 2020 **Sydney, Australia**

Ms Cheng Tang
Adviser
Listings Compliance (Melbourne)
ASX Compliance Pty Limited
Level 4 Rialto North Tower
525 Collins Street
Melbourne VIC 3000

By Email: cheng.tang@asx.com.au
By Email: tradinghaltsmelbourne@asx.com.au

Dear Cheng,

NOXOPHARM LIMITED – TRADING HALT

The Company requests a trading halt effective immediately pending the release of an announcement relating to an update on the Company's capital structure, including capital raising program ("Capital Structure").

The trading halt is requested until the earlier of the release of an announcement relating to the Company's Capital Structure or prior to the opening of trading on Friday 14th February 2020.

The Company is not aware of any reason why the trading halt should not be granted.

Thank you for your assistance. If you have any questions please contact the Company Secretary, David Franks on 0414 899 897.

Yours faithfully,

David Franks
Company Secretary
Noxopharm Limited

About LuPIN-1

LuPIN is an Investigator-Initiated Phase I/II, single-arm, open label study enrolling 56 men with mCRPC whose disease was progressing despite docetaxel, cabazitaxel and either abiraterone and/or enzalutamide. The study is divided into 4 cohorts of 400 mg (8 patients), 800 mg (8 patients), 800 mg (16 patients) and 1200 mg (24 patients) Veyonda® (NOX66) in combination with ^{177}Lu-PSMA-617.

The Phase I part of the study was intended to establish the safety of the combination treatment. The Phase II expansion part is intended to establish the dose-response effect of increasing Veyonda® levels in combination treatment.

Imaging inclusion criteria include a PSMA PET/CT with uptake intensity in metastases more than twice the normal liver uptake and no discordant disease on FDG PET/CT. All men receive up to 6 doses of ^{177} Lu-PSMA 617 at 6-weekly intervals and NOX66 every cycle on days 1-10.

About Veyonda®

Veyonda® is a suppository dosage form of idronoxil, a first-in-class inhibitor of sphingosine-1-phosphate (S1P). S1P is a key secondary messenger in cells, with dual roles of activating major pro-survival signalling pathways and regulating immune cell trafficking in tissues. Many solid cancers over-express S1P, supporting unregulated tumour growth and suppressing immune cell populations and activities in tumours. By inhibiting this over-expression, idronoxil acts as both a radio-sensitiser and an immunotherapy, intended to restore immune function to tumours.

About Noxopharm

Noxopharm is a clinical-stage Australian oncology drug development company with offices in Sydney and New York. The Company has a primary focus on the development of Veyonda® and is the major shareholder in the non-oncology drug development company, Nyrada Inc. (ASX:NYR)

www.noxopharm.com

Ends

…….

Investor & Corporate Enquiries:
Prue Kelly
M: 0459 022 445
E: info@noxopharm.com

Company Secretary:
David Franks
T: +61 2 8072 1400
E: David.Franks@automicgroup.com.au

Media queries:
Catherine Strong
Citadel-MAGNUS
T: 02 8234 0111
E: cstrong@citadelmagnus.com

Graham Kelly, CEO and Chairman of Noxopharm has approved the release of this document to the market.

Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.